LDL Receptor: An open route to feed pancreatic tumor cells.
The role of altered lipid metabolism in pancreatic ductal adenocarcinoma (PDAC) is poorly appreciated. We recently identified the lipid signature of PDAC and revealed low-density lipoprotein receptor (Ldlr) as a metabolic driver of this disease. Here, we comment our findings that disruption of Ldlr leads to intratumoral cholesterol imbalance and improves chemotherapy efficiency.
INSERM, U1068, Centre de Recherche en Cancérologie de Marseille, Marseille, France; Institut Paoli-Calmettes, Marseille, France; CNRS, UMR7258, Marseille, France; Université Aix-Marseille, Marseille, France.
Sophie
S
Vasseur
INSERM, U1068, Centre de Recherche en Cancérologie de Marseille, Marseille, France; Institut Paoli-Calmettes, Marseille, France; CNRS, UMR7258, Marseille, France; Université Aix-Marseille, Marseille, France.
Fabienne
F
Guillaumond
Cholesterol; Ldlr; gemcitabine; mechanisms of oncogenesis and tumor progression; metabolism; novel therapeutic targets; pancreatic cancer; tumor metabolism